US7763430B2 - Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies - Google Patents

Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies Download PDF

Info

Publication number
US7763430B2
US7763430B2 US10/422,052 US42205203A US7763430B2 US 7763430 B2 US7763430 B2 US 7763430B2 US 42205203 A US42205203 A US 42205203A US 7763430 B2 US7763430 B2 US 7763430B2
Authority
US
United States
Prior art keywords
vwf
fragment
domain
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US10/422,052
Other versions
US20040214346A1 (en
Inventor
Friedrich Scheiflinger
Manfred Rieger
Barbara Plaimauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/422,052 priority Critical patent/US7763430B2/en
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Assigned to BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC. reassignment BAXTER HEALTHCARE S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PLAIMAUER, BARBARA, RIEGER, MANFRED, SCHEIFLINGER, FRIEDRICH
Priority to EP04725025A priority patent/EP1616188B1/en
Priority to AU2004232878A priority patent/AU2004232878B2/en
Priority to PCT/EP2004/003483 priority patent/WO2004095027A1/en
Priority to JP2006504955A priority patent/JP4542545B2/en
Priority to CA002522795A priority patent/CA2522795A1/en
Priority to ES04725025T priority patent/ES2406703T3/en
Priority to CN2004800106621A priority patent/CN1777809B/en
Publication of US20040214346A1 publication Critical patent/US20040214346A1/en
Priority to JP2009205368A priority patent/JP2010025941A/en
Priority to US12/829,872 priority patent/US7943326B2/en
Publication of US7763430B2 publication Critical patent/US7763430B2/en
Application granted granted Critical
Assigned to Baxalta GmbH, BAXALTA INCORPORATED reassignment Baxalta GmbH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAXTER HEALTHCARE S.A.
Assigned to BAXALTA INCORPORATED, Baxalta GmbH reassignment BAXALTA INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAXTER INTERNATIONAL INC.
Assigned to BAXALTA INCORPORATED, Baxalta GmbH reassignment BAXALTA INCORPORATED CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036357 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT FROM BAXTER HEALTHCARE SA TO BAXALTA GMBH AND BAXALTA INCORPORATED. Assignors: BAXTER HEALTHCARE SA
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen

Definitions

  • This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (ADAMTS13) antibody (“anti-vWF-cpantibody”) in a sample suspected to comprise an anti-vWF-cp antibody.
  • ADAMTS13 anti-von Willebrand Factor-cleaving protease
  • the kit can be used in a method for diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies in patients, and to discriminate between different forms of thrombotic microangiopathy.
  • vWF von Willebrand Factor
  • Plasma von Willebrand Factor (vWF) is a multimeric protein that mediates adhesion of platelets to sites of vascular injury, and especially the very large vWF multimers are haemostatically competent. The existence of plasma factors that control the size of vWF multimers has long been suspected.
  • the von Willebrand Factor-cleaving protease (“vWF-cp”) is involved in the limitation of platelet thrombus growth by proteolytic cleavage of von Willebrand Factor multimers in man (Furlan et al., (1996) Blood 87: 4223-4234).
  • vWFcp regulates vWF multimer size by proteolytic cleavage.
  • thrombotic thrombocytopenic purpura TTP
  • HUS hemolytic-uremic syndrome
  • TTP Trigger relapsing TTP is associated with acquired or congenital deficiency of vWF-cp.
  • the rare hereditary form of TTP has been related to specific gene mutations in the ADAMTS-13 locus.
  • Acute idiopathic TTP or acquired TTP is usually more severe than chronic relapsing TTP, wherein these patients have acquired antibodies against vWF-cp, which inhibit the von Willebrand Factor-cleaving protease (Furlan et al., (1998) Blood 91: 2839-2846; Furlan et al., (1998) N. Engl. J. Med. 339: 1578-1584).
  • Acquired TTP also occurs occasionally during pregnancy or in the postpartum period. Intermittent relapsing TTP is also associated with the reappearance of vWF-cp inhibitor.
  • TTP For other forms of TTP, such as ticlopidine-associated TTP, it has also been observed that these patients have acquired antibodies against vWF-cp (Moake, (2002) N. Eng. J. Med. 347:589-600). However, some patients with acquired TTP having unusually large vWF multimers in plasma lack severe reduced levels of vWF-cp.
  • inhibitory antibodies against proteins cause serious problems, for example within the coagulation cascade, leading to blood loss or thrombosis.
  • Congenital and acquired TTP are discriminated by the presence of inhibitory antibodies against vWF-cp in the plasma of up to 80% of patients suffering from acquired TTP, and total absence of vWF-cp in plasma of patients with hereditary TTP. So far, inhibitory antibodies in plasma of patients are determined by static enzyme assays under non-physiological conditions and confirm the diagnosis of acute, antibody-mediated TTP.
  • vWF-cp activity and the presence of inhibitors of vWF-cp are determined by incubation of purified vWF multimers with plasma samples of patients, followed by immunoblotting of degraded vWF substrate with anti-vWF antibodies and multimer analysis (Furlan et al., (2002) Sem. Thromb. Haemost. 28:167-172).
  • the method is very sensitive in the range of low protease activity; however, the accuracy is only moderate in the subnormal or normal range of protease activity.
  • a collagen-binding assay for determination vWF-cp activity and vWF-cp inhibitors as described by Gerritsen et al. [(1999) Thromb. Haemost. 82:1386-1389] can be completed within 6 hours, but the method is less sensitive in the very low range of protease activity as compared to the immunoblotting of degraded vWF multimers (Furlan et al. 2002 supra).
  • the assays described in the prior art are very cumbersome, time consuming and require the expertise of laboratories familiar with the technique.
  • the known prior art assays only allow for detection of vWF-cp inhibitors that impair the catalytic function of vWF-cp. Inhibitory antibodies which may impair a vWF-cp function other than the catalytic activity, e.g. endothelial cell binding, cannot be detected by these assays.
  • kits for determination of an anti-vWF-cp antibody in a sample comprises vWF-cp and/or one or more vWF-cp fragment(s) immobilized on a solid phase without substantially impairing the biological property of the vWF-cp or vWF-cp-fragment(s).
  • the kit of the present invention may also contain any auxiliary agents known in the art for carrying out antigen/antibody assays (e.g., ELISA, EIA, RIA etc.), such as buffer salts, buffer disclosed solutions, blocking agents, detecting agents and the like.
  • the kits that are disclosed can be provided in a variety of formats, e.g., in the form of one or more containers or a microtiter plate.
  • vWF-cp or a vWF-cp fragment immobilized on a solid phase provides a simple, efficient, fast and reproducible assay system for determination of the presence of an anti-vWF-cp antibody in a sample.
  • vWF-cp inhibitors have been determined which were not detected in a system of the prior art.
  • the kit of the present invention provides an increased sensitivity in the current assay than prior art assays and can be used to detect vWF-antibodies amounts that may be below the detection limit of known systems.
  • Assays performed with the kit of present invention allows one to discriminate between anti-vWF-cp antibodies having different specificities and based on impairment of different biological functions of vWF-cp.
  • the assay to be performed with the kit of the present invention further allows for a rapid diagnosis of TTP and other disorders associated with vWF-cp inhibitors, as well as differentiation of various forms of thrombotic microangiopathy (TM).
  • TM thrombotic microangiopathy
  • FIG. 1 shows examples of plasmids that can be used for expression of recombinant vWF-cp, vWF-cp-fragment(s), or vWF-cp or vWF-cp-fragment(s) fused to a his-tag heterologous sequence.
  • FIGS. 2A and 2B show the determination of IgG ( FIG. 2A ) and IgM ( FIG. 2B ) antibodies in plasma samples of a patient versus human normal plasma.
  • the error bars indicate the two times added standard deviation of normal human plasma calculated from several plasma lots.
  • One aspect of the invention relates to a kit for determination of an anti-vWF-cp antibody in a sample comprising vWF-cp and/or a vWF-cp fragment immobilized on a solid phase without substantially impairing the biological property of the vWF-cp or the vWF-cp fragment.
  • the vWF-cp or vWF-cp-fragment is used in the kit as diagnostic agent providing the antigenic determination site(s) capable of binding anti-vWF-cp-antibodies present in a sample.
  • determination is meant to include detection, quantification and mapping of the vWF-cp antigen-binding region of an anti-vWF-cp-antibody in a sample.
  • Detection means at least one positive reaction indicating the formation of an antibody/vWF-cp—or an antibody/vWF-cp fragment—complex with a detection system, e.g., a chromogenic assay.
  • a sample known not to comprise any anti-vWF-antibody, e.g., normal human plasma is used as negative control.
  • “Quantification” typically means that defined dilutions of a sample suspected to comprise anti-vWF-cp antibodies are contacted with the immobilized vWF-cp or a vWF-cp fragment, and the intensity of the reaction obtained by the detection system is compared to the intensity of the reaction obtained with defined dilutions of a sample comprising a known and defined amount of anti-vWF-antibodies, which is used as a standard.
  • “Mapping” of the vWF-cp antigen binding site of an anti-vWF-cp antibody is performed by contacting the sample suspected to comprise anti-vWF-cp antibodies with complete vWF-cp as well as with vWF-cp fragments derived from different regions of the vWF-cp molecule. Thereby, the complete spectrum of anti-vWF-cp antibodies possibly present in a sample can be captured and anti-vWF-cp antibodies having specific binding activity within a region/domain of vWF-cp can be identified.
  • sample as used herein is meant to refer to a biological fluid such as blood, plasma or tissue of a patient.
  • the sample may be in particular obtained from human patients suspected of having a disorder associated with occurrence of anti-vWF-cp antibodies
  • solid phase does not imply any specific limitations, and relates, for example, to an unsoluble polymer material, which can be an organic polymer, such as polyamide or a vinyl polymer (e.g., poly(meth)acrylate, polystyrene and polyvinyl alcohol, or derivates thereof), a natural polymer such as cellulose, dextrane, agarose, chitin and polyamino acids, or an inorganic polymer, such as glass or metallohydroxide.
  • the solid phase can be in the form of a microcarrier, particles, membranes, strips, paper, film, pearls or plates, such as microtiter plates.
  • the vWF-cp or vWF-cp fragment(s) can be immobilized on the solid phase directly by covalent coupling or via a carrier such as a linker molecule or an antibody immobilized on the solid phase.
  • biological property as used herein is meant as functionally active epitopes or antigenic determinants of vWF-cp or the vWF-cp fragments, capable of binding at least one anti-vWF-cp antibody.
  • the immobilization of vWF-cp or vWF-cp fragment on a solid phase is performed in such a way that the immunologic properties, in particular the structure of the functional epitopes and antigenic determinants of vWF-cp or the vWF-cp fragments are preserved and efficiently presented to be recognized by at least one anti-vWF-cp antibody present in the sample.
  • the vWF-cp or vWF-cp fragments can be produced in whole or in part by recombinant techniques and can be prepared by expression in a prokaryotic or eukaryotic host system.
  • Prokaryotic hosts can be bacterial cells such as E. coli or B. subtilis .
  • Eukaryotic cells can be selected from the group consisting of yeast cells (e.g., Pichia strains); insect cells (e.g., Sf9, Sf 21, High Five, S2); and mammalian cells, such as MRC5, CHO, COS, 3T3, HEK 293, BHK, SK-Hep, HepG2, CV-1, and Hela.
  • vectors can be used for the preparation of the vWF-cp or vWF-cp fragment(s) and can be selected from eukaryotic and prokaryotic expression vectors.
  • vectors for prokaryotic expression include plasmids such as pRSET, pET, pBAD, etc., wherein the promoters used in prokaryotic expression vectors include lac, trc, trp, recA, araBAD, etc.
  • vectors for eukaryotic expression include: (i) for expression in yeast, vectors such as pAO, pPIC, pYES, pMET, using promoters such as AOX1, GAP, GAL1, AUG1, etc; (ii) for expression in insect cells, vectors such as pMT, pAcS, pIB, pMIB, pBAC, etc., using promoters such as PH, p10, MT, Ac5, OpIE2, gp64, polh, etc., and (iii) for expression in mammalian cells, vectors such as pSVL, pCMV, pRc/RSV, pcDNA3, pBPV, etc., and vectors derived form viral systems such as vaccinia virus, adeno-associated viruses, herpes viruses, retroviruses, etc., using promoters such as CMV, SV40, EF-1 ⁇ , UbC, RSV, ADV, BP
  • the vWF-cp fragment(s) can be selected from the group consisting of SEQ ID NOs1-6.
  • the vWF-cp fragments(s) can be peptides exhibiting amino acid sequences contained in the vWF-cp and having preferably at least 6 amino acids, more preferably from about 6 to about 50 amino acids.
  • One advantage of using said peptides as a diagnostic reagent in the present invention is the selective determination of the specificity of the anti-vWF-cp antibody.
  • the peptides can be produced by standard peptide synthesis techniques.
  • the vWF-cp or the vWF-cp fragment(s) are fused to a heterologous sequence.
  • the heterologous sequence can be heterologous protein, polypeptide or peptide, in particular a functional peptide.
  • the heterologous sequence can be a sequence having binding properties to a solid phase (e.g., the solid phase may have reactive site which allows covalent binding to the heterologous sequence, or has affinity to a carrier).
  • the heterologous protein, polypeptide or peptide can be selected from the group consisting of ⁇ -galactosidase, c-myc-product, glutathione S-transferase, FLAG-tags and derivatives thereof.
  • the heterologous sequence can also comprise a series of several equal or different amino acids.
  • the heterologous sequence is a peptide that can form a covalent bond with the solid phase, or a polyhistidine that has high affinity, particularly to specific anti-poly-histidine antibodies.
  • the heterologous sequence can be fused to vWF-cp or a vWF-cp fragment at either its N- or C-terminus.
  • the heterologous sequence is typically fused to the C-terminal end of vWF-cp.
  • the vWF-cp or a vWF-cp fragment is fused to the heterologous sequence such that the biological property of vWF-cp or a vWF-cp fragment is not negatively affected.
  • a short peptide spacer may be inserted between the heterologous sequence and vWF-cp or a vWF-cp fragment, so as not to impede sterically the presentation of the epitopes of vWF-cp or the vWF-cp fragment.
  • the vWF-cp or a vWF-cp fragment is fused to a functional affinity peptide, in particular a peptide having several histidine residues, in some instances 3 to 20 histidine residues, and in other instances 6 to 15 histidine residues.
  • a functional affinity peptide in particular a peptide having several histidine residues, in some instances 3 to 20 histidine residues, and in other instances 6 to 15 histidine residues.
  • His-tag poly-histidine
  • the immobilization on the solid phase can be effected (e.g., directly or by covalent binding) via reactive groups of the solid phase and the heterologous sequence, or via a carrier having affinity to the heterologous sequence.
  • the heterologous sequence has high affinity to a carrier and the vWF-cp or vWF-cp fragment(s) are immobilized on the solid phase via the binding of its heterologous part to the carrier. Accordingly, the heterologous sequence has specific binding properties or high affinity to the carrier.
  • the carrier is an antibody having affinity to the heterologous part of the vWF-cp fusion protein.
  • vWF-cp or a vWF-cp fragment is fused to a poly histidine-tag as heterologous sequence and an anti-his-tag antibody is used as a carrier to immobilize vWF-cp or the vWF-cp fragment on a solid phase.
  • Other heterologous affinity peptides and respective anti-affinity-peptide antibodies known to the person skilled in the art can also be used to immobilize the vWF-cp or vWF-cp fragment fusion protein.
  • vWF-cp and/or vWF-cp fragment(s), or fusion proteins thereof are immobilized on the solid phase separately on different spots, e.g. in different wells of a microtiter plate, wherein typically one defined antigen such as vWF-cp or a specific vWF-fragment is contained in one spot.
  • typically one defined antigen such as vWF-cp or a specific vWF-fragment is contained in one spot.
  • anti-vWF-cp-antibodies can be selectively removed from the plasma of a patient identified to have specific anti-vWF-cp antibodies by subjecting the patient's plasma to affinity chromatography such as described herein which uses as an adsorbent specific vWF-cp fragments used in the assay and which have affinity to the antibody or antibodies. This allows for an improved treatment of patients having disorders associated with anti-vWF-cp antibodies compared to prior art methods.
  • the kit as described above further comprises as diagnostic agent an anti-vWF-cp antibody immobilized on the solid phase.
  • the anti-vWF-cp antibody can be a monoclonal antibody derived by conventional hybridoma techniques or can be an antibody or antibody fragment obtained by recombinant technique, e.g., phage display or ribosome display.
  • phage display or ribosome display Such a set up in the kit of the present invention allows for differential diagnosis of thrombotic microangiopathic disorders.
  • kits comprising immobilized vWF-cp, vWF-cp fragment(s) and anti-vWF-cp antibody on a solid phase the presence/absence of anti-vWF antibodies as well as the presence/absence of vWF-cp in a sample can be determined with one simple test system.
  • the present invention is also related to a method for determination of an anti-vWF-cp antibody in a sample, comprising the steps of providing vWF-cp and/or one or more vWF-cp fragment(s) immobilized on a solid phase without substantially impairing the biological property of the vWF-cp or vWF-cp fragment(s), contacting a biological sample of a patient suspected of having a disorder associated with the occurrence of anti-vWF-cp antibody with the immobilized vWF-cp and/or one or more vWF-cp fragments, and detecting a complex of anti-vWF-cp antibody/vWF-cp and/or anti-vWF-cp antibody/vWF-cp fragment(s).
  • the complex of anti-vWF-cp antibody/vWF-cp or anti-vWF-cp antibody/vWF-cp fragment(s) can be detected by methods well known in the art, e.g. by detection with a labelled antibody.
  • the detection method can be selected from the group consisting of an enzyme assay, a chromogenic assay, a lumino assay, a fluorogenic assay, and a radioimmune assay.
  • the reaction conditions to perform detection of the antibody/antigen-/complex formation depends upon the detection method selected. It is within the knowledge of the person skilled in the art to choose the optimal parameters, such as buffer system, temperature and pH for the respective detection system to be used.
  • the invention also relates to a method for differential diagnosis of thrombotic microangiopathic disorders with a kit as described above, wherein the kit comprises as diagnostic agent(s) either vWF-cp and/or one or more vWF-fragments, or vWF-cp and/or vWF-fragments and anti-vWF-cp antibodies, immobilized on a solid phase.
  • the diagnostic agents are preferably each located on separate spots on the solid phase, e.g. in separate wells of a microtiter plate. This allows one to differentiate between samples comprising either vWF-cp or anti-vWF-cp antibodies or both by one assay system and to differentiate between thrombotic microangiopathic disorders, e.g. different forms of TTP or HUS.
  • kit and method of the present invention can be used for diagnosis of a disorder associated with occurrence of anti-vWF-cp antibodies.
  • the kit and method of the present invention of the invention can also be used for diagnosis of different forms or disorders of thrombotic microangiopathy.
  • the thrombotic microangiopathic (TM) disorder can be thrombotic thrombocytic purpura (TTP), neonatal thrombocytopenia, Henoch-Schönlein purpura, preclampsia, or hemolytic—uremic syndrome (HUS), HELLP syndrome, ARDS, peripheral digit ischemic syndrome, nonocclusive mesenteric ischemia, acute pancreatitis, acute hepatitis, purpura rheumatica, medicament-associated formation of thrombocytopenia, post-operative TM, cancer-associated TM, disseminated intravascular coagulation (DIC), systemic lupus erythematosus, liver cirrhosis, uremia, or acute inflammatory disorders.
  • TTP thrombotic thrombocytic purpura
  • HUS hemolytic—uremic syndrome
  • kits and a method of the present invention This allows the fast and sensitive diagnosis of TTP and urgent needed life-saving clinical intervention, i.e. plasma treatment.
  • the kit and the method of the present invention can be used for the differential diagnosis of various forms of TTP.
  • kits and the method of the present invention all IgG classes as well as IgM antibodies can be detected, whereas prior art methods only allow detection of anti-vWF-cp antibodies of the IgG class.
  • vWF-cp protein For expression of vWF-cp protein the vWF-cp cDNA clone as described in WO 02/42442 is used.
  • vWF-cp his-tag fusion two consecutive PCRs are carried out to add the codons for 3 ⁇ glycine, 6 ⁇ histidines, stop and a XhoI restriction site.
  • PCR1 the wild-type full length pcDNA3.1.(+)/vWF-cp (ADAMTS13) as described in WO 02/42441 is used as template.
  • primers 7189 5′ GTG ATG GTG ATG GTG TCC ACC TCC GGT TCC TTC CTT TCC CTT CCA3′
  • 6526 5′ CTG CCT CGC CCG GAA CCC CA 3′
  • a 1.3 kb fragment encompassing the C-terminal SgrAI/XhoI fragment from pcDNA3.1.(+)/vWF-cp is amplified.
  • the second PCR is performed.
  • the resulting product is purified, digested with SgrAI and XhoI, and used to replace the corresponding SgrAI/XhoI fragment in pcDNA3.1.(+)/vWF-cp wild-type construct.
  • vWF-cp fragment constructs containing different fragments of the gene of the mature protein are generated by PCR using the following primer combinations (see also Table 4 of Primers and respective vWF-cp domain sequences).
  • E. coli Expression System pBAD/Topo Thiofusion (Invitrogen)
  • PCR fragments are cut with suitable restriction enzymes and cloned into the vector such as pRSET ( FIG. 1 ), and cleaved with the same enzymes resulting in the desired plasmids.
  • vWF-cp fragment(s)-his tag fusions For construction of vWF-cp fragment(s)-his tag fusions, the vWF-cp fragments are modified according to construction of vWF-cp/his-tag as described above.
  • the constructs are cloned with HIS-6 tag by substitution of the Ndel-Xhol fragment by the synthetic oligonucleotides o.pRET-FPdHIS(1)-6929 and o.pRSET-FPdHIS(2)-6930 ( FIG. 1 ).
  • vWF-cp, vWF-cp fragments or the respective his-tag fusions are recombinantly expressed in E. coli JM 109, purified and used for immobilization on a solid phase as described below.
  • HEK 293 (ATCC) cells are co-transfected with pcDNA3.1.(+)/vWF-cp/C-His and a selection plasmid harboring the hygromycine cassette using calcium phosphate precipitation.
  • Initial clones and subsequent subclones are selected in culture medium supplemented with 100 ⁇ g/ml hygromycine and 800 ⁇ g/ml G418 (neomycinphosphotransferase encoded on pcDNA).
  • Recombinant expressed vWF-cp/his—tag is purified and used for immobilization on a solid phase as described below.
  • vWF-cp-His-tag or vWF-cp fragment -His-tag are immobilized via an anti—His tag antibody on the surface of an ELISA plate.
  • anti-vWF-cp antibodies bound to vWF-cp or vWF-cp fragment are detected by a second antibody phosphatase conjugate recognizing the constant human antibody region.
  • the phosphatase reacted with an appropriate substrate resulting in a chromogenic reaction and a yellow color. The intensity of the color is measured and the amount of antibody in the sample is determined by comparison with a standard curve comprising a known amount of anti-vWF antibody.
  • a commercially available, BSA free, anti—His tag antibody (“carrier-antibody”; Qiagen, Germany) is diluted to a final concentration of 2 ⁇ g/mL in PBS pH 7.4. 100 ⁇ l per well is incubated for four hours at room temperature in a 96 well-microtiter plate. After three washing steps using PBST pH 7.4 (PBS buffer containing 0.1% (v/v) Tween 20), 250 ⁇ l of a blocking solution, containing PBS pH 7.4 and 2% (w/v) bovine serum albumin, are added and incubated at 4° C. over night to block all free binding sites.
  • PBST pH 7.4 PBS buffer containing 0.1% (v/v) Tween 20
  • 250 ⁇ l of a blocking solution containing PBS pH 7.4 and 2% (w/v) bovine serum albumin
  • vWF-cp His tag labelled preparation
  • vWF-cp concentration is 1.5 ⁇ g/mL corresponding to 10 U/mL protease activity.
  • vWF-cp samples are diluted to the final concentration in PBS 2% BSA. Due to the coated anti—His antibody recombinant vWFcp/his-tag is captured and immobilized via the carrier antibody. After two hours at room temperature, ten washing steps follow. The washing buffer contains PBS pH7.4 and 0.1% (v/v) Tween 20.
  • Plasma samples of patients are diluted 1:20, 1:50, 1:100, 1:200, 1:300, 1:400, 1:600, 1:800 and 1:1200 in PBS pH 7.4 containing 2% BSA and 100 ⁇ l of each dilution is incubated at room temperature for 3 hours on the recombinant vWF-cp-containing wells.
  • Inhibitory antibodies are bound on the surface of the immobilized vWF-cp and unbound antibodies are washed away by ten washing steps using PBST pH 7.4.
  • Detection of human antibodies is performed with a mouse anti-human IgG Fc specific antibody or mouse anti-human IgM antibody, alkaline phosphatase conjugated.
  • the antibody is diluted 1:60000 in PBS 2% BSA to the final working solution and incubated for 2 hours at room temperature (100 ⁇ l/well), followed by ten washing steps with PBST pH 7.4.
  • Addition of an alkaline phosphatase substrate (PNPP) results in a yellow color, whereby the color intensity reflects the amount of bound antibody (antibody/vWF-cp).
  • PNPP alkaline phosphatase substrate
  • the color intensity is measured in an ELISA reader and the amount of antibody within the plasma sample is calculated in reference to a standard curve of NP by serial dilution.
  • As negative control dilutions of normal human plasma (NHP) are treated accordingly.
  • FIGS. 2A and 2B The results show that human anti-vWF-cp antibodies in a patients can be clearly detected in at least a plasma dilution of 1:600.
  • Normal human plasma is used as control and the standard deviation (SD) calculated for several plasma lots. Antibody titres above that of normal human plasma+2 SD are evaluated as positive.
  • Samples from patients with TTP and normal plasma samples are subjected to ELISA comprising immobilized vWF-cp.
  • the results are shown in Table 1.
  • Patient 1 has an IgG titer of 1:600 and an IgM titer of 1:400.
  • the IgG titer of patient 2 is much higher (1:1200) while the IgM titer is only 1:100.
  • Patient 1 suffers from an acute TTP, while patient 2 is in remission after TTP.
  • Patient 1 shows no inhibitory titer, whereas patient 2 has an inhibitory titer of about 60 U/mL.
  • Normal human plasma shows no reaction.
  • ADAMTS-13 levels of patients #1 and #2 can be clearly detected; normal human plasma shows the same levels.
  • Patient #3 is being characterized to carry a genetic defect on one allele causing a 50% reduced activity. A 50% reduction on protein amount can also be seen in our assay system.
  • Patient #4 is being characterized to completely lack ADAMTS-13 protein due to a homozygous nonsense mutation. Consequently, no protein could be detected.
  • GQGTPSLVPHEEAAAPGRTTATPAGASLEWSQARGLLFSPARQPRRL LPGPQENSVQSSACGRQHLEPTGTIDMRGPCQADCAVAIGR PLGEVVTLRVLESSLNCSAGDMLLLWGRLTRKMCRKLLDMTFSSK TNTLVVRQRCGRPGGGVLLRYGSQLAPETFYRECDMQLFGPWG EIVSPSLSPATSNAGGCRLFINVAPHARIAIHALATNMGAGTEGANA SYILIRDTHSLRTTAFHGQQVLYWESESSQAEMEFSEGFLKAQALRG QYWTLQSWVPEMQDPQSWKGKEGT 7440 (rp) GGTTCCTTCCTTTCCCTTCCAGGACTG

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (“anti-vWF-cp”) antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy.

Description

FIELD OF THE INVENTION
This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (ADAMTS13) antibody (“anti-vWF-cpantibody”) in a sample suspected to comprise an anti-vWF-cp antibody. The kit can be used in a method for diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies in patients, and to discriminate between different forms of thrombotic microangiopathy.
BACKGROUND OF THE INVENTION
One important protein in primary hemostasis is von Willebrand Factor (vWF). Plasma von Willebrand Factor (vWF) is a multimeric protein that mediates adhesion of platelets to sites of vascular injury, and especially the very large vWF multimers are haemostatically competent. The existence of plasma factors that control the size of vWF multimers has long been suspected. The von Willebrand Factor-cleaving protease (“vWF-cp”) is involved in the limitation of platelet thrombus growth by proteolytic cleavage of von Willebrand Factor multimers in man (Furlan et al., (1996) Blood 87: 4223-4234). Recently, the molecular structure of von Willebrand Factor-cleaving protease and the corresponding gene have been described (WO 02/42441; Zheng et al., (2001) J. Biol. Chem. 276: 41059-41063) and have been identified as a new member of the ADAMTS family and designated ADAMTS 13. vWFcp regulates vWF multimer size by proteolytic cleavage.
The large and ultra large vWF multimers play a central role in arterial thrombosis, whereby unusually large mutlimers of vWF have been seen in two similar forms of thrombotic microangiopathy—thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS)—both resulting in formation of platelet aggregation leading to disseminated occlusions in the microcirculation. Patients with TTP have a deficiency of vWF-cp, whereas patients with HUS show normal activity of the protease.
There are several types of TTP: An acute idiopathic or sporadic form, an intermittent form with an eventual relapse, and a chronic relapsing form. Chronic relapsing TTP is associated with acquired or congenital deficiency of vWF-cp. The rare hereditary form of TTP has been related to specific gene mutations in the ADAMTS-13 locus. Acute idiopathic TTP or acquired TTP is usually more severe than chronic relapsing TTP, wherein these patients have acquired antibodies against vWF-cp, which inhibit the von Willebrand Factor-cleaving protease (Furlan et al., (1998) Blood 91: 2839-2846; Furlan et al., (1998) N. Engl. J. Med. 339: 1578-1584). Acquired TTP also occurs occasionally during pregnancy or in the postpartum period. Intermittent relapsing TTP is also associated with the reappearance of vWF-cp inhibitor. For other forms of TTP, such as ticlopidine-associated TTP, it has also been observed that these patients have acquired antibodies against vWF-cp (Moake, (2002) N. Eng. J. Med. 347:589-600). However, some patients with acquired TTP having unusually large vWF multimers in plasma lack severe reduced levels of vWF-cp.
In general, inhibitory antibodies against proteins cause serious problems, for example within the coagulation cascade, leading to blood loss or thrombosis.
Congenital and acquired TTP are discriminated by the presence of inhibitory antibodies against vWF-cp in the plasma of up to 80% of patients suffering from acquired TTP, and total absence of vWF-cp in plasma of patients with hereditary TTP. So far, inhibitory antibodies in plasma of patients are determined by static enzyme assays under non-physiological conditions and confirm the diagnosis of acute, antibody-mediated TTP.
Different assays of vWF-cp for diagnosis of congenital and acquired TTP have been described. vWF-cp activity and the presence of inhibitors of vWF-cp are determined by incubation of purified vWF multimers with plasma samples of patients, followed by immunoblotting of degraded vWF substrate with anti-vWF antibodies and multimer analysis (Furlan et al., (2002) Sem. Thromb. Haemost. 28:167-172). The method is very sensitive in the range of low protease activity; however, the accuracy is only moderate in the subnormal or normal range of protease activity. A collagen-binding assay for determination vWF-cp activity and vWF-cp inhibitors as described by Gerritsen et al. [(1999) Thromb. Haemost. 82:1386-1389] can be completed within 6 hours, but the method is less sensitive in the very low range of protease activity as compared to the immunoblotting of degraded vWF multimers (Furlan et al. 2002 supra). The assays described in the prior art, however, are very cumbersome, time consuming and require the expertise of laboratories familiar with the technique. Moreover, the known prior art assays only allow for detection of vWF-cp inhibitors that impair the catalytic function of vWF-cp. Inhibitory antibodies which may impair a vWF-cp function other than the catalytic activity, e.g. endothelial cell binding, cannot be detected by these assays.
Therefore a need exists for a test system that allows the detection and determination of anti-vWF-cp antibodies in a patient's plasma that impair vWF-cp function other than the enzyme's catalytic protease activity.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a kit for determination of an anti-vWF-cp antibody in a sample. The kit comprises vWF-cp and/or one or more vWF-cp fragment(s) immobilized on a solid phase without substantially impairing the biological property of the vWF-cp or vWF-cp-fragment(s). Additionally, the kit of the present invention may also contain any auxiliary agents known in the art for carrying out antigen/antibody assays (e.g., ELISA, EIA, RIA etc.), such as buffer salts, buffer disclosed solutions, blocking agents, detecting agents and the like. The kits that are disclosed can be provided in a variety of formats, e.g., in the form of one or more containers or a microtiter plate.
Surprisingly, the inventors have found that vWF-cp or a vWF-cp fragment immobilized on a solid phase provides a simple, efficient, fast and reproducible assay system for determination of the presence of an anti-vWF-cp antibody in a sample. With the system of the present invention, vWF-cp inhibitors have been determined which were not detected in a system of the prior art. The kit of the present invention provides an increased sensitivity in the current assay than prior art assays and can be used to detect vWF-antibodies amounts that may be below the detection limit of known systems. Assays performed with the kit of present invention allows one to discriminate between anti-vWF-cp antibodies having different specificities and based on impairment of different biological functions of vWF-cp. The assay to be performed with the kit of the present invention further allows for a rapid diagnosis of TTP and other disorders associated with vWF-cp inhibitors, as well as differentiation of various forms of thrombotic microangiopathy (TM).
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows examples of plasmids that can be used for expression of recombinant vWF-cp, vWF-cp-fragment(s), or vWF-cp or vWF-cp-fragment(s) fused to a his-tag heterologous sequence.
FIGS. 2A and 2B show the determination of IgG (FIG. 2A) and IgM (FIG. 2B) antibodies in plasma samples of a patient versus human normal plasma. The error bars indicate the two times added standard deviation of normal human plasma calculated from several plasma lots.
 DETAILED DESCRIPTION OF THE INVENTION
One aspect of the invention relates to a kit for determination of an anti-vWF-cp antibody in a sample comprising vWF-cp and/or a vWF-cp fragment immobilized on a solid phase without substantially impairing the biological property of the vWF-cp or the vWF-cp fragment. The vWF-cp or vWF-cp-fragment is used in the kit as diagnostic agent providing the antigenic determination site(s) capable of binding anti-vWF-cp-antibodies present in a sample.
The term “determination” as used herein is meant to include detection, quantification and mapping of the vWF-cp antigen-binding region of an anti-vWF-cp-antibody in a sample. “Detection” means at least one positive reaction indicating the formation of an antibody/vWF-cp—or an antibody/vWF-cp fragment—complex with a detection system, e.g., a chromogenic assay. A sample known not to comprise any anti-vWF-antibody, e.g., normal human plasma is used as negative control. “Quantification” typically means that defined dilutions of a sample suspected to comprise anti-vWF-cp antibodies are contacted with the immobilized vWF-cp or a vWF-cp fragment, and the intensity of the reaction obtained by the detection system is compared to the intensity of the reaction obtained with defined dilutions of a sample comprising a known and defined amount of anti-vWF-antibodies, which is used as a standard. “Mapping” of the vWF-cp antigen binding site of an anti-vWF-cp antibody is performed by contacting the sample suspected to comprise anti-vWF-cp antibodies with complete vWF-cp as well as with vWF-cp fragments derived from different regions of the vWF-cp molecule. Thereby, the complete spectrum of anti-vWF-cp antibodies possibly present in a sample can be captured and anti-vWF-cp antibodies having specific binding activity within a region/domain of vWF-cp can be identified.
The term “sample” as used herein is meant to refer to a biological fluid such as blood, plasma or tissue of a patient. The sample may be in particular obtained from human patients suspected of having a disorder associated with occurrence of anti-vWF-cp antibodies
The term “solid phase” does not imply any specific limitations, and relates, for example, to an unsoluble polymer material, which can be an organic polymer, such as polyamide or a vinyl polymer (e.g., poly(meth)acrylate, polystyrene and polyvinyl alcohol, or derivates thereof), a natural polymer such as cellulose, dextrane, agarose, chitin and polyamino acids, or an inorganic polymer, such as glass or metallohydroxide. The solid phase can be in the form of a microcarrier, particles, membranes, strips, paper, film, pearls or plates, such as microtiter plates. The vWF-cp or vWF-cp fragment(s) can be immobilized on the solid phase directly by covalent coupling or via a carrier such as a linker molecule or an antibody immobilized on the solid phase.
The term “biological property” as used herein is meant as functionally active epitopes or antigenic determinants of vWF-cp or the vWF-cp fragments, capable of binding at least one anti-vWF-cp antibody. The immobilization of vWF-cp or vWF-cp fragment on a solid phase is performed in such a way that the immunologic properties, in particular the structure of the functional epitopes and antigenic determinants of vWF-cp or the vWF-cp fragments are preserved and efficiently presented to be recognized by at least one anti-vWF-cp antibody present in the sample.
The vWF-cp or vWF-cp fragments can be produced in whole or in part by recombinant techniques and can be prepared by expression in a prokaryotic or eukaryotic host system. Prokaryotic hosts can be bacterial cells such as E. coli or B. subtilis. Eukaryotic cells can be selected from the group consisting of yeast cells (e.g., Pichia strains); insect cells (e.g., Sf9, Sf 21, High Five, S2); and mammalian cells, such as MRC5, CHO, COS, 3T3, HEK 293, BHK, SK-Hep, HepG2, CV-1, and Hela.
A wide variety of vectors can be used for the preparation of the vWF-cp or vWF-cp fragment(s) and can be selected from eukaryotic and prokaryotic expression vectors. Examples of vectors for prokaryotic expression include plasmids such as pRSET, pET, pBAD, etc., wherein the promoters used in prokaryotic expression vectors include lac, trc, trp, recA, araBAD, etc. Examples of vectors for eukaryotic expression include: (i) for expression in yeast, vectors such as pAO, pPIC, pYES, pMET, using promoters such as AOX1, GAP, GAL1, AUG1, etc; (ii) for expression in insect cells, vectors such as pMT, pAcS, pIB, pMIB, pBAC, etc., using promoters such as PH, p10, MT, Ac5, OpIE2, gp64, polh, etc., and (iii) for expression in mammalian cells, vectors such as pSVL, pCMV, pRc/RSV, pcDNA3, pBPV, etc., and vectors derived form viral systems such as vaccinia virus, adeno-associated viruses, herpes viruses, retroviruses, etc., using promoters such as CMV, SV40, EF-1α, UbC, RSV, ADV, BPV, and β-Actin.
The vWF-cp fragment(s) can be selected from the group consisting of SEQ ID NOs1-6.
The vWF-cp fragments(s) can be peptides exhibiting amino acid sequences contained in the vWF-cp and having preferably at least 6 amino acids, more preferably from about 6 to about 50 amino acids. One advantage of using said peptides as a diagnostic reagent in the present invention is the selective determination of the specificity of the anti-vWF-cp antibody. The peptides can be produced by standard peptide synthesis techniques.
According to one embodiment of the invention, the vWF-cp or the vWF-cp fragment(s) are fused to a heterologous sequence. The heterologous sequence can be heterologous protein, polypeptide or peptide, in particular a functional peptide. The heterologous sequence can be a sequence having binding properties to a solid phase (e.g., the solid phase may have reactive site which allows covalent binding to the heterologous sequence, or has affinity to a carrier).
The heterologous protein, polypeptide or peptide can be selected from the group consisting of β-galactosidase, c-myc-product, glutathione S-transferase, FLAG-tags and derivatives thereof. The heterologous sequence can also comprise a series of several equal or different amino acids. Preferably, the heterologous sequence is a peptide that can form a covalent bond with the solid phase, or a polyhistidine that has high affinity, particularly to specific anti-poly-histidine antibodies. The heterologous sequence can be fused to vWF-cp or a vWF-cp fragment at either its N- or C-terminus. The heterologous sequence is typically fused to the C-terminal end of vWF-cp. The vWF-cp or a vWF-cp fragment is fused to the heterologous sequence such that the biological property of vWF-cp or a vWF-cp fragment is not negatively affected. A short peptide spacer may be inserted between the heterologous sequence and vWF-cp or a vWF-cp fragment, so as not to impede sterically the presentation of the epitopes of vWF-cp or the vWF-cp fragment.
According to one embodiment, the vWF-cp or a vWF-cp fragment is fused to a functional affinity peptide, in particular a peptide having several histidine residues, in some instances 3 to 20 histidine residues, and in other instances 6 to 15 histidine residues. The use of an affinity peptide in the form of poly-histidine (so called “His-tag”) C-terminally fused to a protein for the purification of proteins has been described in EP 0 282 042.
The immobilization on the solid phase can be effected (e.g., directly or by covalent binding) via reactive groups of the solid phase and the heterologous sequence, or via a carrier having affinity to the heterologous sequence.
In one preferred embodiment of the invention, the heterologous sequence has high affinity to a carrier and the vWF-cp or vWF-cp fragment(s) are immobilized on the solid phase via the binding of its heterologous part to the carrier. Accordingly, the heterologous sequence has specific binding properties or high affinity to the carrier. According to one embodiment of the invention, the carrier is an antibody having affinity to the heterologous part of the vWF-cp fusion protein.
In one embodiment of the invention, vWF-cp or a vWF-cp fragment is fused to a poly histidine-tag as heterologous sequence and an anti-his-tag antibody is used as a carrier to immobilize vWF-cp or the vWF-cp fragment on a solid phase. Other heterologous affinity peptides and respective anti-affinity-peptide antibodies known to the person skilled in the art can also be used to immobilize the vWF-cp or vWF-cp fragment fusion protein.
The vWF-cp and/or vWF-cp fragment(s), or fusion proteins thereof, are immobilized on the solid phase separately on different spots, e.g. in different wells of a microtiter plate, wherein typically one defined antigen such as vWF-cp or a specific vWF-fragment is contained in one spot. With this assay system, the complete spectrum of anti-vWF-cp antibodies can be captured and anti-vWF-cp antibodies having specific binding activity within a region/domain of vWF-cp are identified. This is of major importance as by determination of anti-vWF-cp antibody specificity and determination of antigen binding site within the vWF-cp molecule the whole range of antibodies can be identified, and a specific treatment of patients having an anti-vWF-cp antibody associated disorder can be adapted, respectively. For example, anti-vWF-cp-antibodies can be selectively removed from the plasma of a patient identified to have specific anti-vWF-cp antibodies by subjecting the patient's plasma to affinity chromatography such as described herein which uses as an adsorbent specific vWF-cp fragments used in the assay and which have affinity to the antibody or antibodies. This allows for an improved treatment of patients having disorders associated with anti-vWF-cp antibodies compared to prior art methods.
According to one embodiment of the invention, the kit as described above further comprises as diagnostic agent an anti-vWF-cp antibody immobilized on the solid phase. The anti-vWF-cp antibody can be a monoclonal antibody derived by conventional hybridoma techniques or can be an antibody or antibody fragment obtained by recombinant technique, e.g., phage display or ribosome display. Such a set up in the kit of the present invention allows for differential diagnosis of thrombotic microangiopathic disorders. In particular, by providing a kit comprising immobilized vWF-cp, vWF-cp fragment(s) and anti-vWF-cp antibody on a solid phase the presence/absence of anti-vWF antibodies as well as the presence/absence of vWF-cp in a sample can be determined with one simple test system.
The present invention is also related to a method for determination of an anti-vWF-cp antibody in a sample, comprising the steps of providing vWF-cp and/or one or more vWF-cp fragment(s) immobilized on a solid phase without substantially impairing the biological property of the vWF-cp or vWF-cp fragment(s), contacting a biological sample of a patient suspected of having a disorder associated with the occurrence of anti-vWF-cp antibody with the immobilized vWF-cp and/or one or more vWF-cp fragments, and detecting a complex of anti-vWF-cp antibody/vWF-cp and/or anti-vWF-cp antibody/vWF-cp fragment(s).
The complex of anti-vWF-cp antibody/vWF-cp or anti-vWF-cp antibody/vWF-cp fragment(s) can be detected by methods well known in the art, e.g. by detection with a labelled antibody. The detection method can be selected from the group consisting of an enzyme assay, a chromogenic assay, a lumino assay, a fluorogenic assay, and a radioimmune assay. The reaction conditions to perform detection of the antibody/antigen-/complex formation depends upon the detection method selected. It is within the knowledge of the person skilled in the art to choose the optimal parameters, such as buffer system, temperature and pH for the respective detection system to be used.
The invention also relates to a method for differential diagnosis of thrombotic microangiopathic disorders with a kit as described above, wherein the kit comprises as diagnostic agent(s) either vWF-cp and/or one or more vWF-fragments, or vWF-cp and/or vWF-fragments and anti-vWF-cp antibodies, immobilized on a solid phase. The diagnostic agents are preferably each located on separate spots on the solid phase, e.g. in separate wells of a microtiter plate. This allows one to differentiate between samples comprising either vWF-cp or anti-vWF-cp antibodies or both by one assay system and to differentiate between thrombotic microangiopathic disorders, e.g. different forms of TTP or HUS.
The kit and method of the present invention can be used for diagnosis of a disorder associated with occurrence of anti-vWF-cp antibodies.
The kit and method of the present invention of the invention can also be used for diagnosis of different forms or disorders of thrombotic microangiopathy. The thrombotic microangiopathic (TM) disorder can be thrombotic thrombocytic purpura (TTP), neonatal thrombocytopenia, Henoch-Schönlein purpura, preclampsia, or hemolytic—uremic syndrome (HUS), HELLP syndrome, ARDS, peripheral digit ischemic syndrome, nonocclusive mesenteric ischemia, acute pancreatitis, acute hepatitis, purpura rheumatica, medicament-associated formation of thrombocytopenia, post-operative TM, cancer-associated TM, disseminated intravascular coagulation (DIC), systemic lupus erythematosus, liver cirrhosis, uremia, or acute inflammatory disorders.
The Examples provided herein clearly show that the presence of an anti-vWF-cp antibody in an acquired TTP patient, non-neutralizing in a standard vWF-cp activity assay but most likely impairing vWF-cp activity by mechanisms different from simply blocking substrate-cleaving activity, can be determined using a kit and a method of the present invention. This allows the fast and sensitive diagnosis of TTP and urgent needed life-saving clinical intervention, i.e. plasma treatment. The kit and the method of the present invention can be used for the differential diagnosis of various forms of TTP.
With the kit and the method of the present invention, all IgG classes as well as IgM antibodies can be detected, whereas prior art methods only allow detection of anti-vWF-cp antibodies of the IgG class.
The present invention will be further illustrated in the following examples, without any limitation thereto.
EXAMPLE 1 Construction of a vWF-cp and vWF-cp Fragment/His(6×)-tag
For expression of vWF-cp protein the vWF-cp cDNA clone as described in WO 02/42442 is used.
To construct a vWF-cp his-tag fusion, two consecutive PCRs are carried out to add the codons for 3× glycine, 6× histidines, stop and a XhoI restriction site.
PCR1: the wild-type full length pcDNA3.1.(+)/vWF-cp (ADAMTS13) as described in WO 02/42441 is used as template. With primers 7189 (5′ GTG ATG GTG ATG GTG TCC ACC TCC GGT TCC TTC CTT TCC CTT CCA3′) and 6526 (5′ CTG CCT CGC CCG GAA CCC CA 3′) a 1.3 kb fragment encompassing the C-terminal SgrAI/XhoI fragment from pcDNA3.1.(+)/vWF-cp is amplified. Using this fragment and primers 7190 (5′ CCC TCT AGA CTC GAG TCA ATG GTG ATG GTG ATG GTG TCC ACC 3′) and 6526, the second PCR is performed. The resulting product is purified, digested with SgrAI and XhoI, and used to replace the corresponding SgrAI/XhoI fragment in pcDNA3.1.(+)/vWF-cp wild-type construct.
Using the full length vWF-cp cDNA clone disclosed in WO 02/42442 as template, vWF-cp fragment constructs containing different fragments of the gene of the mature protein are generated by PCR using the following primer combinations (see also Table 4 of Primers and respective vWF-cp domain sequences).
E. coli Expression System: pBAD/Topo Thiofusion (Invitrogen)
Fusion: Thioredoxin (N-terminal), 6xHis-tail (C-terminal)
DNA-fragment
(bp) protein-fragment (aa) region in ADAMTS13
 88-222  30(P)-74(R) Propeptid
 223-1317  75(A)-439(E) Cat./Disintegr./tsp1#1
1156-1317  386(R)-439(E) Tsp1#1
1318-2055  440(K)-685(A) Cys-rich/spacer
2056-3393  686(W)-1131(V) tsp1#2-8
3394-4281 1132(G)-1427(T) Cub1 + 2
The PCR fragments are cut with suitable restriction enzymes and cloned into the vector such as pRSET (FIG. 1), and cleaved with the same enzymes resulting in the desired plasmids.
For construction of vWF-cp fragment(s)-his tag fusions, the vWF-cp fragments are modified according to construction of vWF-cp/his-tag as described above. The constructs are cloned with HIS-6 tag by substitution of the Ndel-Xhol fragment by the synthetic oligonucleotides o.pRET-FPdHIS(1)-6929 and o.pRSET-FPdHIS(2)-6930 (FIG. 1).
The vWF-cp, vWF-cp fragments or the respective his-tag fusions are recombinantly expressed in E. coli JM 109, purified and used for immobilization on a solid phase as described below.
HEK 293 Cell Clone Stably Expressing vWF-cp/C-His
HEK 293 (ATCC) cells are co-transfected with pcDNA3.1.(+)/vWF-cp/C-His and a selection plasmid harboring the hygromycine cassette using calcium phosphate precipitation. Initial clones and subsequent subclones are selected in culture medium supplemented with 100 μg/ml hygromycine and 800 μg/ml G418 (neomycinphosphotransferase encoded on pcDNA). Recombinant expressed vWF-cp/his—tag is purified and used for immobilization on a solid phase as described below.
EXAMPLE 2 Coupling of vWF-cp and/or vWF-cp Fragment(s) on a Carrier
Recombinant vWFcp, vWF-cp fragment(s) are either coupled directly on a solid phase, or via monoclonal anti-vWF-cp antibodies as carriers. vWF-cp-His-tag or vWF-cp fragment -His-tag are immobilized via an anti—His tag antibody on the surface of an ELISA plate. After incubation with a patient's plasma, anti-vWF-cp antibodies bound to vWF-cp or vWF-cp fragment are detected by a second antibody phosphatase conjugate recognizing the constant human antibody region. The phosphatase reacted with an appropriate substrate resulting in a chromogenic reaction and a yellow color. The intensity of the color is measured and the amount of antibody in the sample is determined by comparison with a standard curve comprising a known amount of anti-vWF antibody.
ELISA Setup:
A commercially available, BSA free, anti—His tag antibody (“carrier-antibody”; Qiagen, Germany) is diluted to a final concentration of 2 μg/mL in PBS pH 7.4. 100 μl per well is incubated for four hours at room temperature in a 96 well-microtiter plate. After three washing steps using PBST pH 7.4 (PBS buffer containing 0.1% (v/v) Tween 20), 250 μl of a blocking solution, containing PBS pH 7.4 and 2% (w/v) bovine serum albumin, are added and incubated at 4° C. over night to block all free binding sites. The solution is replaced by 100 μl of a recombinant vWF-cp—His tag labelled preparation. vWF-cp concentration is 1.5 μg/mL corresponding to 10 U/mL protease activity. vWF-cp samples are diluted to the final concentration in PBS 2% BSA. Due to the coated anti—His antibody recombinant vWFcp/his-tag is captured and immobilized via the carrier antibody. After two hours at room temperature, ten washing steps follow. The washing buffer contains PBS pH7.4 and 0.1% (v/v) Tween 20. Plasma samples of patients are diluted 1:20, 1:50, 1:100, 1:200, 1:300, 1:400, 1:600, 1:800 and 1:1200 in PBS pH 7.4 containing 2% BSA and 100 μl of each dilution is incubated at room temperature for 3 hours on the recombinant vWF-cp-containing wells. Inhibitory antibodies are bound on the surface of the immobilized vWF-cp and unbound antibodies are washed away by ten washing steps using PBST pH 7.4. Detection of human antibodies is performed with a mouse anti-human IgG Fc specific antibody or mouse anti-human IgM antibody, alkaline phosphatase conjugated. The antibody is diluted 1:60000 in PBS 2% BSA to the final working solution and incubated for 2 hours at room temperature (100 μl/well), followed by ten washing steps with PBST pH 7.4. Addition of an alkaline phosphatase substrate (PNPP) results in a yellow color, whereby the color intensity reflects the amount of bound antibody (antibody/vWF-cp). The color intensity is measured in an ELISA reader and the amount of antibody within the plasma sample is calculated in reference to a standard curve of NP by serial dilution. As negative control, dilutions of normal human plasma (NHP) are treated accordingly. The results are presented in FIGS. 2A and 2B. The results show that human anti-vWF-cp antibodies in a patients can be clearly detected in at least a plasma dilution of 1:600.
Normal human plasma is used as control and the standard deviation (SD) calculated for several plasma lots. Antibody titres above that of normal human plasma+2 SD are evaluated as positive.
Analysis of TTP Patient Samples
Samples from patients with TTP and normal plasma samples are subjected to ELISA comprising immobilized vWF-cp. The results are shown in Table 1. Patient 1 has an IgG titer of 1:600 and an IgM titer of 1:400. The IgG titer of patient 2 is much higher (1:1200) while the IgM titer is only 1:100. Patient 1 suffers from an acute TTP, while patient 2 is in remission after TTP. Patient 1 shows no inhibitory titer, whereas patient 2 has an inhibitory titer of about 60 U/mL. Normal human plasma shows no reaction.
TABLE 1
Anti-vWF-cp antibody detection ELISA. IgG as well as IgM titers of two patients.
1:20 1:50 1:100 1:200 1:300 1:400 1:600 1:800 1:1200
IgG#1 + + + + + + + + + + + + + + + + + + + − −
IgM#1 + + + + + + + + + + + + + + − − −
NP − − − − − − − − −
IgG#2 + + + + + + + + + + + + + + + + + + + + + + + + + +
IgM#2 + + + + + − − − − − −
NP − − − − − − − − −
Samples of patients with TTP and normal plasma samples are subjected to ELISA comprising immobilized vWF-cp fragments derived from different regions of vWF-cp. The results are shown in Table 2. IgGs and IgMs of patient #1 (no inhibitory titer) show binding of antibodies on domains trombospondin 2-8 and the Cub domains. IgGs and IgMs of patient #2 show binding on the catalytic domain, which is consistent to the inhibitory titer. Normal human plasma does not react with any domain. Patient's plasma is tested in duplicates and two different plasma dilutions (1:50 and 1:100).
TABLE 2
Analysis of the binding on different ADAMTS-13 fragments of patient's antibodies
Catalytic, Catalytic, Cys-
Catalytic Catalytic disintegrin, disintegrin, Cys-rich, rich, Tsp Tsp CUB CUB
domain, domain, tsp1 tsp1 spacer, spacer, 2-8, 2-8, 1 + 2 1 + 2
1:50 1:100 1:50 1:100 1:50 1:100 1:50 1:100 1:50 1:100
IgG#1 − − − − − − + + + + −
IgM#1 − − − − − − + + + + −
NP − − − − − − − − − −
IgG#2 + + + + + + + + + + + − − − − −
IgM#2 + + + + + − − − − − −
NP − − − − − − − − −
Samples of patients with TTP and from normal plasma are subjected to ELISA comprising immobilized anti-vWF-cp antibody. The results are shown in Table 3.
ADAMTS-13 levels of patients #1 and #2 can be clearly detected; normal human plasma shows the same levels. Patient #3 is being characterized to carry a genetic defect on one allele causing a 50% reduced activity. A 50% reduction on protein amount can also be seen in our assay system. Patient #4 is being characterized to completely lack ADAMTS-13 protein due to a homozygous nonsense mutation. Consequently, no protein could be detected.
TABLE 3
Detection of ADAMTS-13 levels in plasma using anti-vWF-cp antibodies for capturing.
1:20 1:50 1:100 1:200 1:300 1:400 1:600 1:800 1:1200
ADAMTS-13 + + + + + + + + + + + + + + + + + + + + + + + + −
#1
ADAMTS-13 + + + + + + + + + + + + + + + + + + + + + + + + −
#2
ADAMTS-13 + + + + + + + + + + + + + + − − −
#3
ADAMTS-13 − − − − − − − − −
#4
NP + + + + + + + + + + + + + + + + + + + + + + + + −
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent or patent application were specifically and individually indicated to be so incorporated by reference.
TABLE 4
PRIMER ADAMTS-13
(Baxter #) DNA sequence (5′ → 3′) DOMAIN PRIMARY SEQUENCE
7442 (dp) CCCTCCCATTTCCAGCAGAGTTGTCTT Propeptid SEQ ID. 1:
PSHFQQSCLQALEPQAVSSYLSPGAPLKGRPPSPGFQRQRQRQRR
7443 (rp) CCGCCTCTGCCTCTGCCTCTG
7359 (rp) CTCGCAGGCCTGAGTGTTGCACATCTC Catalytic/ SEQ ID. 2:
disintegrin/ AAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLG
Tsp-1/#1 AQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPEDD
TDPGHADLVLYITRFKLEDPDGNRQVRGVTQLGGACSPTWSCLIT
EDTGFDLGCTIAHEIGHSFGLEHDGAPGSGCGPSGHVMASDGAA
PRAGLAWSPCSRRQLLSLLSAGRARCVWDPPRPQPGSAGHPPD
AQPGLYYSANEQCRVAFGPKAVACTFAREHLDMCQALSCHTDPL
DQSSCSRLLVPLLDGTECGVEKWCSKGRCRSLVELTPIAAVHG
RWSSWGPRSPCSRSCGGGVVTPPPQCNNPRPAFGGRACVGAD
LQAEMCNTQACE
7360 (dp) GCTGCAGGCGGCATCCTACACCTG
7600 (dp) CGCTGGTCTAGCTGGGGTCCC Tsp-1//#1 SEQ ID. 3:
RWSSWGPRSPCSRSCGGGVVTPPPQCNNPRPAFGGRACVGAD
LQAEMCNTQACE
7601 (rp) CTCGCAGGCCTGAGTGTTGCA
7357 (rp) GGCCTGCCGTGGCTTAGGCTGGAAGTA Cystein-rich/ SEQ ID. 4:
spacer KTQLEFMSQQCARTDCQPLRSSPGGASFYHWGAAVPHSQGDAL
CRHMCRAIGESFIMKRGDSFLDGTRCMPSGPREDGTLSLCVSGS
CRTFGCDCRMDSQQVWDRCQVCGGDNSTC
SPRKGSFTAGRAREYCTFLTCTPNLTSCYIANHRPLFTHLAVRIGG
RYVVAGKMSISPNTTYPSILLEDGRVEYRVALTEDRLPRLEEIRIW
GPLQEDADIQVYRRYGEEYGNLTRPDITFTYFQPKPRQA
7358 (dp) AAGACCCAGCTGGAGTTCATGTCGCAA
7441 (dp) TGGGTGTGGGCCGCTGTGCGT Tsp-1/ SEQ ID. 5:
#2–8 WVWAAVRGPCSVSSGAGLRWVNQSCLDQARKELVETVQCQGSQQPPA
WPEACVLEPCPPYWAVGDFGPCSASCGGGLRERPVRCVEAQGSLLKT
LPPARCRAGAQQPAVALETCNPQPCPARWEVSEPSSCTSAGGAGLAL
ENETCVPGADGLEAPVTEGPGSVDEKLPAPEPCVGMSCPPGWGHLDA
TSAGEKAPSPWGSIRTGAQAAHVWTPVAGSCSVSCGRGLMELRFLCM
DSALRVPVQEELCGLASKPGSRREVCQAVPCPARWQYKLAACSVSCG
RGVVRRILYCARAHGEDDGEEILLDTQCQGLPRPEPQEACSLEPCPP
RWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEACAALVRPE
ASVPCLIADCTYRWHVGWMECSVSCGDGIQRRRDTCLGPQAQAPVPA
DFCQHLPKPVTVRGCWAGPCV
7444 (rp) CACACAGGGCCCAGCCCAGCA
7439 (dp) GGACAGGGTACGCCCAGCCTG Cub 1+2 SEQ ID. 6:
GQGTPSLVPHEEAAAPGRTTATPAGASLEWSQARGLLFSPARQPRRL
LPGPQENSVQSSACGRQHLEPTGTIDMRGPCQADCAVAIGR
PLGEVVTLRVLESSLNCSAGDMLLLWGRLTRKMCRKLLDMTFSSK
TNTLVVRQRCGRPGGGVLLRYGSQLAPETFYRECDMQLFGPWG
EIVSPSLSPATSNAGGCRLFINVAPHARIAIHALATNMGAGTEGANA
SYILIRDTHSLRTTAFHGQQVLYWESESSQAEMEFSEGFLKAQALRG
QYWTLQSWVPEMQDPQSWKGKEGT
7440 (rp) GGTTCCTTCCTTTCCCTTCCAGGACTG

Claims (7)

1. A method for detecting an anti-von Willebrand Factor-cleaving protease (“anti-vWF-cp”) antibody in a sample, where the antibody binds to a catalytic domain, a thrombospondin 2-8 domain, or a Cub domain of a vWF cp fragment, comprising the steps of
(a) providing a solid phase comprising an immobilized vWF-cp fragment fused to a heterologous sequence that is separated from the vWF-cp fragment by a spacer, wherein the biological property of said vWF-cp fragment is not substantially impaired and the presentation of the epitopes of the vWF-cp fragment is not sterically impeded, and further, wherein the vWF-cp fragment comprises the catalytic domain, the thrombospondin 2-8 domain, or the Cub domain;
(b) contacting a biological sample of a patient suspected of having thrombotic thrombocytopenic purpura (TTP) associated with occurrence of the anti-vWF-cp antibody with said immobilized vWF-cp fragment; and
(c) detecting a complex of the anti-vWF-cp antibody and the vWF-cp fragment, wherein the presence of a complex with the catalytic domain is indicative of the presence of inhibitory antibodies that impair the catalytic function of substrate cleavage and the presence of a complex with the thrombospondin 2-8 domain or the cub domain is indicative of the presence of antibodies that do not inhibit substrate cleavage.
2. The method according to claim 1, wherein the solid phase is selected from the group consisting of plates, membranes, paper, film, strips, and pearls.
3. The method according to claim 1, wherein said complex is detected by an assay selected from the group consisting of an enzyme assay, a chromogenic assay, a lumino assay, a fluorogenic assay, and a radioimmune assay.
4. A method for diagnosis of thrombotic thrombocytopenic purpura (TTP) in a patient having or suspected of having, a form of TTP comprising the steps of
(a) providing a solid phase comprising immobilized vWF-cp fragment fused to a heterologous sequence that is separated from the vWF-cp fragment by a spacer, wherein the biological property of said vWF-cp fragment is not substantially impaired and the presentation of the epitopes of the vWF-cp fragment is not sterically impeded, and further, wherein the vWF-cp fragment comprises a catalytic domain, a thrombospondin 2-8 domain, or a Cub domain;
(b) contacting a biological sample of a patient suspected of having TTP associated with occurrence of an anti-vWF-cp antibody with said immobilized vWF-cp fragment;
(c) detecting formation of a complex of the anti-vWF-cp antibody and immobilized vWF-cp fragment, thereby diagnosing and/or discriminating between different forms of TTP, wherein the presence of a complex with the catalytic domain is indicative of the presence of inhibitory antibodies that impair the catalytic function of substrate cleavage and the presence of a complex with the thrombospondin 2-8 domain or the cub domain is indicative of the presence of antibodies that do not inhibit substrate cleavage; and
(d) determining a vWF-cp level in a plasma sample from the patient and comparing the vWF-cp level in the plasma sample with a level of vWF-cp in a sample of normal plasma,
wherein the detection of the complex of anti-vWF-cp antibody from the biological sample and immobilized vWF-cp fragment, and determination of a vWF-cp level in the plasma sample from the patient that is the same as the level in normal plasma indicates that the form of TTP is acquired TTP.
5. The method according to claim 4, wherein said solid phase in step (a) further comprises an immobilized anti-vWF-cp antibody.
6. The method according to claim 1 wherein the vWF-cp fragment is the catalytic domain, the thrombospondin 2-8 domain, or the Cub domain.
7. The method according to claim 4, wherein the vWF-cp fragment is the catalytic domain, the thrombospondin 2-8 domain or the Cub domain.
US10/422,052 2003-04-22 2003-04-22 Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies Expired - Lifetime US7763430B2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/422,052 US7763430B2 (en) 2003-04-22 2003-04-22 Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
EP04725025A EP1616188B1 (en) 2003-04-22 2004-04-01 Diagnostic assay for anti-von willebrand factor cleaving protease (adamts13) antibodies
AU2004232878A AU2004232878B2 (en) 2003-04-22 2004-04-01 Diagnostic assay for anti-von willebrand factor cleaving protease (ADAMTS13) antibodies
PCT/EP2004/003483 WO2004095027A1 (en) 2003-04-22 2004-04-01 Diagnostic assay for anti-von willebrand factor cleaving protease (adamts13) antibodies
JP2006504955A JP4542545B2 (en) 2003-04-22 2004-04-01 Diagnostic Assay for Anti-Von Bilvirant Factor Cleaving Protease (ADAMTS13) Antibody
CA002522795A CA2522795A1 (en) 2003-04-22 2004-04-01 Diagnostic assay for anti-von willebrand factor cleaving protease (adamts13) antibodies
ES04725025T ES2406703T3 (en) 2003-04-22 2004-04-01 Diagnostic assay for von Willebrand factor cleavage anti-protease antibodies (ADAMTS13)
CN2004800106621A CN1777809B (en) 2003-04-22 2004-04-01 Diagnostic assay for anti-von willebrand factor cleaving protease (ADAMTS13) antibodies
JP2009205368A JP2010025941A (en) 2003-04-22 2009-09-04 Diagnostic assay for anti-von willebrand factor cutting protease (adamts13) antibody
US12/829,872 US7943326B2 (en) 2003-04-22 2010-07-02 Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/422,052 US7763430B2 (en) 2003-04-22 2003-04-22 Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/829,872 Division US7943326B2 (en) 2003-04-22 2010-07-02 Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies

Publications (2)

Publication Number Publication Date
US20040214346A1 US20040214346A1 (en) 2004-10-28
US7763430B2 true US7763430B2 (en) 2010-07-27

Family

ID=33298787

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/422,052 Expired - Lifetime US7763430B2 (en) 2003-04-22 2003-04-22 Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
US12/829,872 Expired - Lifetime US7943326B2 (en) 2003-04-22 2010-07-02 Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/829,872 Expired - Lifetime US7943326B2 (en) 2003-04-22 2010-07-02 Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies

Country Status (8)

Country Link
US (2) US7763430B2 (en)
EP (1) EP1616188B1 (en)
JP (2) JP4542545B2 (en)
CN (1) CN1777809B (en)
AU (1) AU2004232878B2 (en)
CA (1) CA2522795A1 (en)
ES (1) ES2406703T3 (en)
WO (1) WO2004095027A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550939A1 (en) * 2003-12-22 2005-07-07 Mitsubishi Kagaku Iatron, Inc. Method of detecting thrombosis by measuring von willebrand factor-cleaving protease
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
JP4875495B2 (en) * 2004-11-08 2012-02-15 三菱化学メディエンス株式会社 Method for detecting platelet thrombosis or organ damage
EP1686176A1 (en) 2005-01-28 2006-08-02 Icon Genetics AG Production of antibodies in plants with plus-sense single-stranded viral RNA vectors
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
WO2006133955A1 (en) * 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
JP5067917B2 (en) * 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Separation and purification method of ADAMTS13
US20090004673A1 (en) * 2006-01-31 2009-01-01 Mitsubishi Kagaku Iatron, Inc. Method for Determining Condition of Disseminated Intravascular Coagulation
DE102007031708A1 (en) * 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Determination of von Willebrand factor activity in the absence of ristocetin
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
AU2012255027B2 (en) * 2011-05-19 2015-09-24 Takeda Pharmaceutical Company Limited Detection of circulating ADAMTS13-antibody complexes
RU2641234C2 (en) * 2011-11-20 2018-01-16 Эф-Ай-Оу Корпорейшн Method, system and device for quality control using sensors for use with devices for biological/ecological rapid diagnostic tests
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
CN106442969B (en) * 2016-08-23 2018-08-31 中国人民解放军军事医学科学院微生物流行病研究所 A kind of kit for detecting botulinum toxin
CN106596936B (en) * 2016-12-19 2019-05-31 吴江华药生物技术有限公司 Method, detection kit and the preparation method of Quantitative in vitro measurement vWF-CP enzymatic activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008335A (en) * 1994-02-11 1999-12-28 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and Crohn's disease
WO2002042441A2 (en) 2000-11-22 2002-05-30 Baxter Aktiengesellschaft VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE
US20030228284A1 (en) * 2002-04-30 2003-12-11 University Of North Carolina At Chapel Hill Secretion signal vectors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050904A1 (en) * 1999-02-25 2000-08-31 Baxter Aktiengesellschaft Test kit for analysing factor viii-splitting protease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008335A (en) * 1994-02-11 1999-12-28 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and Crohn's disease
WO2002042441A2 (en) 2000-11-22 2002-05-30 Baxter Aktiengesellschaft VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE
US20030228284A1 (en) * 2002-04-30 2003-12-11 University Of North Carolina At Chapel Hill Secretion signal vectors

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Additivity of Mutational Effects in Proteins. Biochemistry 29(37): 8509-8517. *
Brenner (Apr. 1999) "Errors in genome annotation." Trends in Genetics 15(4): 132-133;). *
Furlan, M. et al. "Acquired Deficiency of von Willebrand Factor-Cleaving Protease in a Patient With Thrombotic Thrombocytopenic Purpura", Blood, Apr. 15, 1998; pp. 2839-2846, vol. 91, No. 8.
Furlan, M. et al. "Assays of von Willebrand Factor-Cleaving Protease: A Test for Diagnosis of Familial and Acquired Thrombotic Thrombocytopenic Purpura", Seminars in Thrombosis and Hemostasis, 2002, pp. 167-172, vol. 28, No. 2.
Furlan, M. et al. "Partial Purification and Characterization of a Protease From Human Plasma Cleaving von Willebrand Factor to Fragments Produced by In Vivo Proteolysis", Blood, May 15, 1996; pp. 4223-4234, vol. 87, No. 10.
Furlan, M. et al. "Von Willebrand Factor-Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndrome", New England Journal of Medicine, Nov. 26, 1998; pp. 1578-1584, vol. 339, No. 22.
Gerritsen, H et al. " Assays of von Willebrand Factor (vWF)-Cleaving Protease Based on Decreased Collagen Binding Affinity of Degraded vWF", Thromb Haemost, 1999, pp. 1386-1389, vol. 82.
Moake, J. "Thrombotic Microangiopathies", New England Journal of Medicine, Aug. 22, 2002; pp. 589-600, vol. 347, No. 8.
Smith and Zhang (Nov. 1997) The challenges of genome sequence annotation or 'The devil is in the details'. *
The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox pp. 492-495. *
Tsai et al. (Ann. Intern Med. 2001 vol. 132, p. 794-799). *
Zheng, X et al. "Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura", J Biological Chemistry, Nov. 2, 2001, pp. 41059-41063, vol. 276, No. 44, Printed in the U.S.A.

Also Published As

Publication number Publication date
AU2004232878A1 (en) 2004-11-04
US7943326B2 (en) 2011-05-17
EP1616188A1 (en) 2006-01-18
US20040214346A1 (en) 2004-10-28
JP2006524321A (en) 2006-10-26
JP2010025941A (en) 2010-02-04
ES2406703T3 (en) 2013-06-07
CN1777809A (en) 2006-05-24
CA2522795A1 (en) 2004-11-04
US20100273183A1 (en) 2010-10-28
JP4542545B2 (en) 2010-09-15
EP1616188B1 (en) 2013-03-06
AU2004232878B2 (en) 2009-05-28
CN1777809B (en) 2013-08-21
WO2004095027A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
US7943326B2 (en) Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
US5741658A (en) Quantitative clotting assay for activated factor VII
JP2006524321A5 (en)
JP2019035765A (en) Modification-dependent activity assay
US7863009B2 (en) Mutants of the factor VII-activating protease and detection methods using specific antibodies
US20050186646A1 (en) Rapid assay to detect ADAMTS-13 activity
De Willige et al. Increased N‐terminal cleavage of alpha‐2‐antiplasmin in patients with liver cirrhosis
US10209263B2 (en) Methods of measuring adamts 13 activity
AU2008259839A1 (en) Compositions and methods for modulation of ADAMTS13 activity
US20070275414A1 (en) Method of Detecting Thrombosis by Measuring Von Willenbrand Factor-Cleaving Protease
JP7358241B2 (en) Detection method and composition therefor
US20080286803A1 (en) Method for the Functional Determination of Mannan-Binding-Lectin Associated Serine Proteases (Masps) and Complexes Thereof
Sabino et al. Development of a collagen-binding activity assay as a screening test for type II von Willebrand disease in dogs
WO1995027209A1 (en) Method and kit for detection of thrombin receptor activation of platelets and other cells
US20050153383A1 (en) Synthetic and recombinant substrates for the detecion of the von willebrand factor-cleaving protease
JPH06174721A (en) Method of measuring lupus anticoagulant substance antibody and measuring reagent
US7691641B2 (en) Polysaccharide-peptide conjugates for use as thrombin substrates
JPH0827282B2 (en) Immunological assay method for human protein C, assay reagent and kit thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHEIFLINGER, FRIEDRICH;RIEGER, MANFRED;PLAIMAUER, BARBARA;REEL/FRAME:013869/0724

Effective date: 20030730

Owner name: BAXTER INTERNATIONAL INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHEIFLINGER, FRIEDRICH;RIEGER, MANFRED;PLAIMAUER, BARBARA;REEL/FRAME:013869/0724

Effective date: 20030730

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: BAXALTA GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER HEALTHCARE S.A.;REEL/FRAME:036357/0001

Effective date: 20150811

Owner name: BAXALTA INCORPORATED, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER HEALTHCARE S.A.;REEL/FRAME:036357/0001

Effective date: 20150811

Owner name: BAXALTA GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER INTERNATIONAL INC.;REEL/FRAME:036366/0517

Effective date: 20150811

Owner name: BAXALTA INCORPORATED, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER INTERNATIONAL INC.;REEL/FRAME:036366/0517

Effective date: 20150811

AS Assignment

Owner name: BAXALTA GMBH, SWITZERLAND

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036357 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT FROM BAXTER HEALTHCARE SA TO BAXALTA GMBH AND BAXALTA INCORPORATED;ASSIGNOR:BAXTER HEALTHCARE SA;REEL/FRAME:036412/0001

Effective date: 20150811

Owner name: BAXALTA INCORPORATED, ILLINOIS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036357 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT FROM BAXTER HEALTHCARE SA TO BAXALTA GMBH AND BAXALTA INCORPORATED;ASSIGNOR:BAXTER HEALTHCARE SA;REEL/FRAME:036412/0001

Effective date: 20150811

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552)

Year of fee payment: 8

AS Assignment

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAXALTA GMBH;BAXALTA INCORPORATED;REEL/FRAME:055189/0005

Effective date: 20201205

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12